What is the appropriate management for a patient who missed their scheduled Cabenuva (cabotegravir plus rilpivirine) injection by two months?

Management of Cabenuva Missed by 2 Months

For a patient who missed their Cabenuva injection by 2 months, you must "reload" the regimen with two initiation doses separated by 4 weeks before returning to the regular every-2-month schedule. 1

Understanding the Delay

A 2-month delay means the patient is now 16 weeks or more from their last injection (assuming they were on the every-2-month schedule after completing initiation). This exceeds the critical threshold that requires restarting the loading phase.

Specific Management Algorithm

Step 1: Clinical Reassessment

Before resuming injections, clinically reassess the patient to determine if continuing injectable therapy remains appropriate 2. This is crucial because:

• The patient has been without adequate antiretroviral coverage for an extended period
• Risk of virologic failure and potential resistance development exists
• You need to verify the patient's commitment to the injection schedule

Step 2: HIV Testing

Perform HIV RNA testing (viral load) before reinitiating injections to:

• Confirm current virologic status
• Rule out virologic failure during the gap period
• Detect any potential resistance that may have developed

Step 3: Reloading Protocol

Administer the full initiation sequence:

• First injection: 600 mg cabotegravir (3 mL) + 900 mg rilpivirine (3 mL) gluteal IM
• Second injection: Same doses exactly 4 weeks (1 month) later
• Subsequent injections: Continue every 2 months thereafter 1, 2

This reloading requirement applies because the delay was ≥16 weeks from the previous injection (for injection 3 or later). The FDA label specifies that delays >3 months from the last injection require this two-dose reinitiation sequence 2.

Critical Distinction from Guidelines

Important caveat: The 2025 IAS-USA guidelines recommend reloading for delays of 8 or more weeks (16+ weeks from previous injection for injection 3 and beyond), which is more conservative than the current FDA package insert 1. This guideline recommendation prioritizes maintaining adequate drug levels to prevent virologic failure and resistance development.

Bridging Therapy Consideration

While the patient has already missed the injection by 2 months, for future prevention of such gaps:

• Patients should have a 1-month supply of tenofovir-based oral PrEP on hand for bridging if injection delays of 7+ days occur 1
• If the patient has ongoing HIV exposure risk during the gap period, consider whether oral bridging therapy should have been used

Common Pitfalls to Avoid

1. Do not simply resume the every-2-month schedule without the reloading doses—this risks subtherapeutic drug levels
2. Do not use the monthly dosing schedule as an alternative—the patient needs the full initiation sequence
3. Do not skip the clinical reassessment—this delay may indicate adherence challenges that could affect future success with injectable therapy
4. Do not forget both injections—cabotegravir AND rilpivirine must both be given at each visit

Patient Counseling

After reloading, emphasize:

• The importance of keeping scheduled appointments (every 2 months after completing the two loading doses)
• Having oral backup medication available for future potential delays
• Contacting the clinic immediately if they anticipate missing an appointment

This reloading approach ensures adequate drug concentrations are re-established to maintain virologic suppression and minimize resistance risk 1, 2.